Aurisco Pharmaceutical (605116) Fundamentals 2026 — P/E 20.2x, Revenue Analysis | SniperIQ
Aurisco Pharmaceutical (605116) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥7.9B, trading at ¥19.35 on the SHH. This SniperIQ fundamentals page covers Aurisco Pharmaceutical's valuation (P/E 20.2x, P/B 2.8x), profitability (net margin 23.4%), revenue (¥1.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Aurisco Pharmaceutical's market cap?
Aurisco Pharmaceutical (605116) has a market capitalization of approximately ¥7.9B, trading at ¥19.35 on the SHH. Market cap moves with the live share price.
What is Aurisco Pharmaceutical's P/E ratio?
Aurisco Pharmaceutical's trailing twelve-month P/E ratio is 20.2x, with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Aurisco Pharmaceutical?
Aurisco Pharmaceutical runs a net profit margin of 23.4%, a gross margin of 57.3%, and an operating margin of 27.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Aurisco Pharmaceutical generate?
Aurisco Pharmaceutical reported revenue of ¥1.7B for fiscal year 2025, with net income of ¥449M and earnings per share (EPS) of 1.12. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Aurisco Pharmaceutical pay a dividend?
Aurisco Pharmaceutical offers a trailing dividend yield of about 1.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Aurisco Pharmaceutical financially healthy?
Aurisco Pharmaceutical carries a debt-to-equity ratio of 0.36x and a current ratio of 4.22x, with a market beta of -0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Aurisco Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Aurisco Pharmaceutical (605116) the key facts are: market cap ¥7.9B, P/E 20.2x, revenue ¥1.7B, 52-week range 18.09-35.58. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Aurisco Pharmaceutical's full fundamentals live
Get Aurisco Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.